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Abstract
In this study, rat bone marrow stromal stem cells (BMSCs) were tracked after IV administration to rats with experimental
stroke caused by middle cerebral artery occlusion (MCAO). In addition, the effects of BMSC treatment on blood cell
composition, brain glia and sensorimotor behavior was studied and compared to that which occurred spontaneously during
the normal recovery process after stroke. We found that the vast majority of radiolabeled or fluorescently labeled BMSCs
traveled to and remained in peripheral organs (lungs, spleen, liver) 3 days after IV injection in the MCAO rat. Once in the
circulation, BMSCs also produced rapid alterations in host blood cell composition, increasing both neutrophil and total
white blood cell count by 6 hours post-injection. In contrast, few injected BMSCs traveled to the brain and almost none
endured there long term. Nonetheless, BMSC treatment produced dramatic changes in the number and activation of brain
astroglia and microglia, particularly in the region of the infarct. These cellular changes were correlated with a marked
improvement in performance on tests of sensory and motor function as compared to the partial recovery of function seen in
PBS-injected control rats. We conclude that the notable recovery in function observed after systemic administration of
BMSCs to MCAO rats is likely due to the cellular changes in blood and/or brain cell number, activation state and their
cytokine/growth factor products.
Citation: Goldmacher GV, Nasser R, Lee DY, Yigit S, Rosenwasser R, et al. (2013) Tracking Transplanted Bone Marrow Stem Cells and Their Effects in the Rat MCAO
Stroke Model. PLoS ONE 8(3): e60049. doi:10.1371/journal.pone.0060049
Editor: Cesar V. Borlongan, University of South Florida, United States of America
Received December 12, 2012; Accepted February 20, 2013; Published March 29, 2013
Copyright:  2013 Goldmacher et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors gratefully acknowledge The Joe and Marie Field Foundation for their generous support of this work. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lorraine.iacovittti@jefferson.edu
Introduction
Currently, stroke is the leading cause of disability and the
second leading cause of death worldwide. With the advent of anti-
thrombosis treatment in the last decade [1,2], the mortality rate
associated with stroke has declined somewhat (12%). However,
since only a small fraction of ischemic patients benefit from anti-
thrombotic therapy, the overall incidence of stroke continues to
climb, as does its enormous burden on society (for review, [3].
Therefore, developing new ways to treat stroke remains of utmost
importance.
Stem cells, with their ability to both stimulate endogenous repair
mechanisms and replace dying neurons offer great promise as a
potential stroke therapy [4,5]. Indeed, studies over the last decade
have shown a marked improvement in brain structure and
function following stem cell transplant, regardless of the route of
cell delivery (intraparenchymal, intraventricular, intravenous; IV)
[6,7] or the type of stem cell administered (bone marrow, umbilical
cord blood, ES cells) (for review, [8,9]). Despite this progress, there
remain fundamental gaps in our understanding regarding the fate
of stem cells once transplanted and the mechanism of action
underlying their beneficial effects.
In this study, we have employed imaging techniques to track the
journey followed by radiolabeled or fluorescently labeled rat bone
marrow stromal stem cells (BMSCs) after IV injection into rats
with experimental stroke caused by middle cerebral artery
occlusion (MCAO). In addition, the effects of BMSC treatment
on blood cell composition, brain glia and sensorimotor behavior
have been chronicled during an extended period following
infarction and compared to those that occur during normal
spontaneous recovery from stroke. We will show that while brain
structure and function can partially recover from experimental
stroke, IV administration of BMSCs greatly increases the extent of
that recovery. The latter occurs despite the fact that the vast
majority of BMSCs remain in the periphery after systemic
injection into the MCAO rat where they produce changes in
blood cell composition. Likewise, in the brain where few injected
BMSCs endure long term, there are dramatic changes in the
number and activation of astroglia and microglia in the region of
the infarct that is correlated with an improvement in behavioral
measures. We conclude that the sustained recovery in sensorimo-
tor function observed in BMSC-treated MCAO rats is likely due to
the changes in blood and/or brain cells and/or their cytokine/
growth factor products.
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Materials and Methods
Animals
Ethics Statement. All procedures in this study were carried
out in accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the IACUC Committee of
the Thomas Jefferson University (Protocol Number: 457I). All
surgery was performed under anesthesia, and all efforts were made
to minimize suffering.
MCAO lesion. Adult, male, Sprague-Dawley rats weighing
275–350 grams were anesthetized using 60 mg/kg SQ ketamine
hydrochloride, 10 mg/kg xylazine and 5 mg/kg acepromazine
maleate. When necessary, depending on a reflex withdrawal
response and breathing rate, maintenance doses of 10 mg/kg SQ
ketamine hydrochloride, 1.5 mg/kg xylazine and 0.75 mg/kg
acepromazine maleate were administered to maintain anesthesia.
Atropine (0.054 mg/kg, SQ) was given during the procedure to
decrease bronchial secretions and keep up the heart rate. Core
body temperature was monitored with a rectal temperature probe,
and maintained with a heating pad and/or a small fan to within
0.5uC.
Rats were shaved and artificial tears ointment was applied to the
animal’s eyes for protection and lubrication. The surgical site was
scrubbed with Betadine, Chlorhexidine, and 70% ethyl alcohol.
The animal was positioned in a prone position. A midline incision
was made and the skull is thinned over the right parietal cortex
(5 mm lateral and 1 mm posterior to Bregma) without injury to
the dura mater with the burr hole. The laser Doppler was attached
to the skull with dental cement. Cerebral blood flow was measured
starting before, during and after ischemia (Blood Flow Meter, AD
Instruments, Colorado Springs, CO). Then the animal was placed
supine, and the MCAO performed. Briefly, the right common
carotid (CCA) and external and internal carotid arteries (ECA,
ICA) were exposed through a 2 cm midline incision. Using an
operating microscope, the right CCA was ligated at the proximal
end. Then the right ECA was ligated just distal to the branch of
occipital artery. A microvascular clamp was used to temporarily
occlude the pterygoplatine artery. The occipital artery was
separated and cauterized. Then a 3-0 silk suture was used to
place a slack knot around the right CCA between the first ligature
and the bifurcation. Right ICA blood flow was then interrupted by
clamping with a microvascular clip at its origin. A tiny opening on
the right CCA was made between the first ligature and the slack
knot. A silicone rubber-coated monofilament nylon suture
(diameter with coating is 0.39 mm, Doccol) was then inserted
into the lumen of the CCA through this opening. The slack silk
suture was then constricted around the CCA over the nylon suture
to avoid bleeding. The clamps were removed and the nylon suture
was carefully advanced into the ICA until it obstructed the MCA
(18 mm from the bifurcation of the CCA). Occlusion produced on
average a 40–70% decline in blood flow as detected by laser
Doppler. Two hours later, the constricted suture over the CCA
was loosened and the filament removed for reperfusion of the
brain. Sham operated animals were anesthetized and underwent
surgery and brain microdissection as described above but without
tying off of the arteries.
BMSC harvest and cell culture. Rat BMSCs were harvest-
ed from SD rats (Harlan) or from a transgenic rat cell line in which
the human placental alkaline phosphatase (Alk phos) gene was
placed under the control of the human ROSA26 regulatory
element (Invitrogen). In brief, bone marrow cells were flushed
from the shaft of the femur bone with PBS. Cells were then plated
into medium containing 15% FCS, 1% nonessential amino acids,
1% glutamine, 1% pen-strep in DMEM. Cells were passaged 6–8
times before use in transplantation studies.
Cell labeling and transplantation procedures. For iso-
tope labeling, cells were harvested in 200 uL of PBS. 1.1 mCi of
In-111 oxine in 1 ml of PBS was added. Cells were incubated with
tracer for 30 minutes at RT, followed by repeated rinses to remove
unbound activity. BMSCs were isolated from the Alk phos
transgenic rat line, allowing for the histochemical visualization of
individually tagged BMSCs. Alk-phos-labeled BMSCs were
harvested from culture using standard methods and tracked in
vivo via histochemistry using the ELFH 97 Endogenous Phospha-
tase Detection Kit (Invitrogen) and visualized using an Olympus
IX81 Image System. Labeled or unlabeled rat BMSCs were
harvested from culture, centrifuged (1000 RPM) and the pellet re-
suspended in sterilized PSB and injected 56105 cells in 0.5 mL of
sterile saline into the rat tail vein after MCAO surgery.
Imaging Methods. To assess the functional deficits associat-
ed with infarction, we injected 18F-Fluorodeoxyglucose (FDG)
intravenously into rats one day post-MCAO. Animals were fasted
for 6 hours prior to each scan to eliminate any elevations in blood
glucose at the time of the scan. In brief, the rat was anesthetized
with Ketamine-Xylazine-Acepromizine mixture i.p. before the
injection of tracer to avoid unnecessary uptake of tracer into the
muscles due to the movement of the rat. We injected approxi-
mately 350 mCi of 18F-FDG intravenously through tail vein. The
rat continued to be under the effect of anesthesia for another
90 minutes, during which time imaging procedures were per-
formed. An Inveon pre-clinical PET scanner (Siemens, Knoxville,
TN) was used for PET imaging. A 10 min PET acquisition was
performed at 45 min from the time of injection of tracer in
addition to the 10 min transmission imaging. A CT scan was
performed in MicroCAT II CT scanner (Siemens, Knoxville, TN)
after the PET imaging. After the scan, the animals were placed in
quarantine in a biohazard hood. Rats were not returned to the
animal colony until the radiation had completely decayed to
background (24 hours for 18F).
For real-time tracking of injected BMSCs, rats were transported
to the TJU small animal imaging facility. Usually 1–2 but no more
than 4 animals were studied in any one session. To trace the fate of
injected In-111 labeled BMSCs, cells were resuspended and slowly
infused into the tail vein of a rat 24 hrs after MCAO surgery,
followed by 0.5 ml of PBS ‘‘chaser’’ (final injected activity was
approximately 570 uCi). CT-imaging was performed using a
gamma camera. (each scan lasting up to 30 minutes) at 1 hour,
2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours,
36 hours, and 48 hours after injection. Whole body images were
obtained using a flat collimator and a pinhole collimator was used
to capture brain images. The animals were anesthetized using 2%
isoflurane for imaging and were allowed to recover between
imaging time points any time the imaging interval was greater
than 1 hour. The rats were monitored in the animal imaging
facility until fully awake and recovered. Imaging was repeated for
3 sham-lesioned and 3 MCAO lesioned rats.
Blood Cell Analysis. To track changes in circulating blood
cell populations following IV injection of BMSC’s, host blood was
collected from the tail vein before and 24 hr after MCAO and 6
and 24 hr after BMSC treatment. Blood was collected in 2 ml
tubes spray-dried with 1.2–2.0 mg EDTA/1 mL of blood (Fischer
Scientific Cat No. 22-040-101), samples were kept at 4uC and sent
them to Bioreliance (Rockville, MD) for blood cell analysis. Briefly,
cells were separated using an automated system that employs the
ADVIA 120 Hematology analyzer to perform differential CBC
assay using cytochemical light scatter and light absorption
measurements and LIMS software analysis [10].
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Behavioral Tests. To evaluate neurological function before
and after stem cell transplant, rats were subjected to a battery of
tests before and after MCAO and transplantation. Motor deficits
were evaluated using a modified Neurological Severity Score
(mNSS) [11] which includes fore and hind limb flexion; walking,
righting, placing, balance, body resistance, paralysis). Using this
scale, one point was given for the inability to perform a test.
Consequently, the higher the score, the more severe is the motor
deficit (maximum score = 18). In addition, motor function was
assessed using a forelimb use asymmetry test [12–14], wherein rats
were placed in a plexiglass cylinder and the number of attempts to
climb the sidewalls with impaired (I), unimpaired (U) and both (B)
limbs was quantified during a 10 min trial. The asymmetry index
was calculated as [U/(U+I+B)] – [I/(U+I+B)] [12–14]. The higher
the index, the greater is the asymmetry in use. We also used a
corner test wherein rats were placed in a 30 degree corner and the
percentage of turns to the right (unimpaired side) was calculated
for 15 trials [12,15]. Since normal rats turn 50% of the time
towards the right and 50% toward the left side, the higher the
score, the greater the MCAO-induced deficit. Behavior was
assessed at regular intervals by an observer blinded to treatment
status.
Immunocytochemistry. Transplanted rat brains were per-
fused with 4% cold (4uC) periodate-lysine-paraformaldehyde,
sectioned at 30 mm on a freezing microtome and processed for
immunocytochemistry using the immunofluorescence staining
method described previously [16]. Cultures or sections through
brain, spleen, liver and heart were stained with one or more of the
following antibodies: mouse anti-human nuclear antigen (HNA)
from Millipore at 1:40; rabbit antibodies to GFAP, 1:1000;
monoclonal mouse antibodies to CD11, 1:25. All secondary
antibodies were Alexa Fluor antibodies from Invitrogen used at
1:200–1:300. Cultures or sections were analyzed using a Nikon-
Scanalytics Image System or an Olympus IX81 Image System.
After immunostaining, five regions of interest surrounding the
infarct on the side of MCAO, and comparable regions in the
contralateral and PBS control striatum, were quantified in 10
sections through each forebrain. Image J software (http://rsb.info.
nih.gov/ij/) was used to quantify pixel intensity values and percent
relative values determined. The data were analyzed using
GraphPad Prism software with a non-paired Student’s t-test.
TTC Staining method. Following sacrifice, fresh (unfixed)
brain was removed from the skull, washed in iced PBS and placed
in a brain mold. Coronal sections 1 mm in thickness were cut
through the cerebrum and placed in 1% 2,3, 5 triphenyltetrazo-
lium chloride (TTC; Sigma) for 30 min in a 3uC incubator. TTC
solution was drained and sections were immersed in 4% formalin
in 0.1 m PB at 4uC and stained as described previously [16].
Statistical Analysis. Data were statistically analyzed by one-
way analysis of variance. When P,0.05, then the F-test was
followed by the two-tailed Students t-test to compare the statistical
significance between control and experimental groups (ANOVA
with subsequent post-hoc analysis using Bonferroni correction).
Statistical differences were considered significant only when the P
value was,0.05.
Results
Assessing stroke and its effects
To assess functional change in the brain and body, fluorodeox-
yglucose (18F) (FDG) utilization was imaged in rats for up to a
month following experimental stroke and compared to sham-
operated controls (n = 3). Reconstruction was performed with 3D-
OSEM algorithm to get high resolution images of brain
metabolism. A CT scan was performed after the PET imaging
and image registration was used to align CT images and PET
images. PET-CT fusion images were used to identify anatomical
landmarks. Regions of interest (ROI) were drawn on the PET
images to measure the amount of glucose metabolism in different
parts of the brain. From these, we calculated the size of the infarct
and the improvement in uptake at different time points (1, 4
weeks). We found that using FDG, one could image the region and
functional loss after MCAO and even assess the improvement
which occurs spontaneously over time (example provided in
Fig. 1). Note that over a 4 week recovery period, slice 3, near the
greatest area of infarct, spontaneously recovered only 4% while
slices 2 and 4–6 showed greater recovery (8–22%) and slices 1 and
7 where there is collateral circulation from the anterior and
posterior cerebral were less affected (10%) by occlusion of the
MCA.
Importantly, the improvement reported above was accompa-
nied by a substantial degree of spontaneous recovery in some but
not all sensorimotor behaviors. In studies done to date on MCAO
rats, the modified Neurological Severity Score (mNSS) has been
the most widely used scale of behaviors to assess changes in
neurological function [11]. As anticipated, after a major infarct in
the brain, there was a significant decline in sensorimotor function
on mNSS score (Mean score of 14/18) at 1 day post-MCAO (set to
100%) (N = 5–8). However, 1 week later, deficits were markedly
reduced (27% improvement in the mNSS score; Fig. 2A) in
infarcted rats receiving only palliative care, due particularly to
improvements in gait, body resistance and spontaneous move-
ment. By 2–4 weeks after injury, there was further recovery that
plateaued when the mNSS score reached approximately 50% of
the original 1 day post-MCAO score. In contrast, other behaviors,
such as, use of the impaired forelimb in climbing (Fig. 2B), and
ability to turn toward both left and right in the corner test
(Fig. 2C), which relies on both sensory function of the vibrissae
and motor function on the impaired side [12,15], did not show
substantial spontaneous recovery in function over the course of a
month.
In vivo tracking of radioisotope-labeled BMSCs in MCAO
rats. As little is yet known about the path that BMSCs travel
after their injection into the bloodstream, we tracked the journey
of radioisotope-labeled BMSCs in rats with moderate to severe
stroke. To do so, BMSCs (8.16106 cells) were harvested and
grown as described by us previously [16]. For isotope labeling,
BMSCs were harvested in 200 uL of PBS. 1.1 mCi of In-111 oxine
in 1 ml of PBS was added. Cells were incubated with tracer for
30 minutes at RT, followed by repeated rinses to remove unbound
activity. Cells were re-suspended and slowly infused into the tail
vein of a rat 24 hrs after MCAO surgery, followed by 0.5 ml of
PBS ‘‘chaser’’ (final injected activity was approximately 570 uCi).
Imaging was performed using a gamma camera. Whole body
images were obtained using a flat collimator, at 4, 20, 44 and
70 hrs after injection, with 350,000 counts collected for each
image. We found that the vast majority of IV-injected cells
traveled to the lungs where they remained 3 days later. In
addition, activity in the liver and spleen increased over time
(Fig. 3A). Images of the brain were obtained using a pinhole
collimator at 20, 44 and 70 hours, with 100,000 counts collected
for each image. By 44 and 70 hours, higher brain activity was
observed on the side ipsilateral to the infarct, suggesting that
MSCs had in fact homed to the site of brain injury (Fig. 3B).
Tracking Stem Cells and Their Effects after Stroke
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Figure 1. Analysis of infarct severity and extent on PET/CT imaging in representative sham and MCAO brains. A. Coronal view of a
sham-operated animal showing normal symmetrical glucose uptake. B. One day post-MCAO, there is decreased uptake on the side of the infarct. C.
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Tracking transplanted alkaline phosphatase labeled
BMSCs in MCAO rats
Although the radioisotope imaging technique is useful as a first
level of investigation, resolution at the cellular level requires
additional analysis. Therefore, we used a labeling technique which
allows for histochemical visualization of individual Alk phos tagged
BMSCs (Invitrogen). BMSCs (derived as described in Methods)
robustly expressed Alk phos during cell expansion and differen-
tiation in culture (Fig. 4A inset). After IV injection into the
MCAO rat tail vein, Alk phos-tagged cells were readily detected in
the lung (Fig. 4A) and in the brain at days 3 post-transplant
(Fig. 4B). However, most labeled BMSCs in the brain had
vanished by 8 days post-transplant although some remained at the
edge of the infarcted region (Fig. 4C).
Changes in host cells after BMSC treatment in MCAO rats:
Analysis of Host Blood Cell Composition
Although many labs have examined the effects of BMSCs in the
brain, no one has tracked their effects on host blood cells. To assess
changes in blood cell populations following IV injection of
BMSC’s, the blood was collected from the tail vein before and
24 hr after MCAO and 6 and 24 hr after BMSC injection. We
found that MCAO procedure alone produced an increase in
neutrophils, a decrease in lymphocytes and no change in other cell
types or the total white blood cell count (Fig. 5). However, by
6 hours after BMSC treatment, there was a further amplification
in the number of neutrophils, resulting in an increase in the total
while blood cell count despite the fact that lymphocytes remained
unchanged from MCAO-induced levels (Fig. 5). Importantly, by
24 h hours after stem cell treatment, all cell counts reverted to
pretreatment or post-MCAO levels.
Analysis of BMSC Effects on the Brain
As shown previously [16–18], BMSC treatment produces
significant changes in local brain cells beyond that which occurs
due to MCAO. Thus, by 1 week (data not shown) and continuing
at 4 weeks post-injection (Fig. 6A), rats administered BMSCs
24 hrs after MCAO exhibited a marked increase in the number of
reactive GFAP+ astrocytes (412%629% relative fluorescence
intensity) and CD11+ microglia (487%617% relative fluorescence
intensity) in the area surrounding the infarct compared to the
contralateral side (100%69% relative fluorescence intensity) or
PBS-treated MCAO rats (98%612%). In addition, glia and
microglial cells in the stem cell-treated rats exhibited an activated
morphology, shown in Fig. 6B insets, at 4 weeks, long after their
counterparts in untreated MCAO rats had returned to the
quiescent state (Fig. S1), as noted previously [16].
Recovery of function after BMSCs treatment in MCAO
rats
Importantly, changes seen in the brain after BMSC treatment
were correlated with functional recovery of sensorimotor behav-
iors when compared to control rats (PBS-treated). Thus, stem cell
treatment resulted in a significant improvement in neurologic
function (ie. mNSS score) (Fig. 7A) over the partial recovery seen
spontaneously after MCAO (Fig. 2A). In addition, BMSC
treatment significantly improved other long-lasting measures of
sensorimotor function, such as cylinder climbing capacity and left
corner turning ability, both of which did not show signs of
spontaneous recovery (Figs. 7B,C). In all of these cases, BMSC-
induced recovery in behavioral deficits did not reach significance
until 4 weeks after treatment was initiated.
Discussion
Numerous studies have chronicled the remarkable ability of
systemic BMSCs to produce recovery of brain structure and
function after experimental stroke in rats [9,16,19–23]. However,
few if any studies have adequately assessed the degree to which
these indices improve spontaneously over time without interven-
tional treatment. In addition, relatively few studies have actually
Axial and coronal images showing placement of 2 mm thick ovoid regions of interest (ROIs) [symmetrical across the midline, arbitrary colors] across
the cerebral hemispheres. D. Mean standardized uptake value (SUV) ratios (infarcted to contralateral side ROI) are plotted against slice position
comparing infarcted and sham-operated control rat shown in A–C. The severity of the infarct is reflected both by the number of slices affected, and
the degree to which activity is suppressed (relative to normal) in each slice. Over 4 weeks, there was a modest spontaneous improvement in FDG
uptake, which correlated with the improvement seen in mNSS scores from 6 to 4 (not shown). Imaging was repeated for 3 sham-lesioned and 3
MCAO lesioned rats.
doi:10.1371/journal.pone.0060049.g001
Figure 2. Spontaneous recovery of behavioral deficits after MCAO. Panel A represents sensorimotor loss as measured by the mNSS score.
mNSS scores are normalized to a maximum of 18 on the mNSS scale (100% deficit). Note that following MCAO there was substantial spontaneous
recovery in the mNSS score. N= 4–6, *p,0.01 and **p,0.001 compared to scores at 1 d post-MCAO. Panel B represents the rats’ ability to climb the
sidewall of a cylinder using the affected limb after MCAO. All rats were tested prior to MCAO and at 1, 2, 3 and 4 weeks after MCAO and the
asymmetry index calculated (See Methods). Note that the decline in forelimb climbing remained even at 4 weeks post-MCAO. N=4–6, ** p,0.001.
Panel C represents the ability of the test animal to turn toward the unimpaired right side when placed in a corner. All rats are tested prior to MCAO,
turning 50% of the time to the right and 50% of the time to the left. Values represent % of trials in which the rat turned toward the unimpaired side
after MCAO. Note that following MCAO, this ability declined dramatically. ** p,0.001. In all 3 panels, the higher the value, the greater the deficit.
(N = 4–8 6 SEM).
doi:10.1371/journal.pone.0060049.g002
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tracked the journey taken by stem cells after their systemic
administration and documented their effects in blood and brain
during the recovery period [24–26]. The current study demon-
strates that the brain is indeed capable of considerable spontane-
ous recovery in structure and function after experimental stroke
but that systemic BMSC treatment, which affects both blood and
brain cell composition, provides added benefit, improving all
indices examined, particularly at later post-recovery times.
Until now, the role of spontaneous recovery of function after
MCAO has not been well-investigated. The present study however
found that even after a large MCAO-induced infarction, there was
a partial but significant restoration in brain glucose function. In
fact, the high demand for energy in the brain is almost exclusively
provided by the oxidative metabolism of glucose. Importantly,
brain regions at greater distances from the infarct showed
considerable (22%) spontaneous recovery of glucose utilization,
while contrastingly, areas of greatest infarct showed much less
recovery of glucose function (4%). These findings suggest that most
rescue in glucose function occurs in the penumbra region
surrounding the infarct, as has been noted previously [27–29].
Moreover, regions with greater collateral blood circulation from
the anterior and posterior cerebral arteries are able to sustain a
drop in blood flow without significant decline in glucose
utilization.
In examining how functional changes in glucose uptake
correlated with changes in sensorimotor function, a somewhat
different profile emerged, depending on the behavioral assessment.
We found that during the first 1–2 weeks after MCAO, there was a
substantial degree of recovery in the mNSS score, which assesses a
wide range of motor and sensory skills. The recovery stemmed
mainly from improvements in gait, body resistance and sponta-
neous activity in MCAO rats. However, by, 2 weeks post-MCAO,
this recovery plateaued, with no further improvement at later
times. In contrast to the mNSS score, other sensorimotor tests
affected by MCAO remained unchanged one month later. Thus,
there was no spontaneous recovery in the ability to use the affected
limb to climb the sidewalls of a cylinder and virtually no
improvement in the rats’ ability to turn towards the impaired
side in the corner test one month after MCAO. While both of the
latter tests assess motor function, the corner test also depends upon
sensory stimulation of the vibrissae to induce turning behavior
[12,15]. Thus, in judging the success of new therapies for stroke,
caution must be exercised as some behaviors partially improve
spontaneously over time after MCAO, while others do not.
Additionally, our study examined whether therapeutic treat-
ment with systemic BMSCs could ameliorate the deficits in brain
structure and function caused by MCAO, enhancing recovery
beyond that which occurs spontaneously. Despite the wide array of
studies describing stem cells and their effects after experimental
stroke in the rat [9,16,19,20,22,23,30], little is known about the
route that BMSCs take in the body and brain when administered
directly into the peripheral circulation. In our imaging experi-
Figure 3. Whole body and brain images following IV injection of In-111 oxine–labeled BMSCs. (A) Images show persistent activity in the
lungs, with relative activity in the liver (arrows) and spleen (arrowheads) increasing over time. Bladder activity is also seen. (B) Brain images at various
times after injection. Larger magnification through a pinhole collimator with increasing proximity to the forebrain in later images (20 hrs, 44 hrs,
70 hrs) showed higher activity on the side of the infarct. Approximate position of left eye is marked in each image. (N = 4).
doi:10.1371/journal.pone.0060049.g003
Figure 4. Alkaline phosphatase labeled rBMSCs in vitro and after IV administration into MCAO rats. Panel A.: Lung sections 3 days after
transplantation; BMSCs show intense activity in the small airways. Note distinct green punctate Alk Phos histochemical staining. Inset: Human alk
phos in BMSCs in culture. B. Brain sections from the same animal showing activity in the peri-infarcted tissue. C. Brain at 8 days after transplantation
shows some activity at the edge of the infarct zone (‘‘I’’ = infarct, with no intact tissue). (N = 3) Scale bars in A,C= 100 um; B = 50 um.
doi:10.1371/journal.pone.0060049.g004
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ments, we found that most IV-injected BMSCs remained in the
periphery, lodging in the lung, the first capillary bed reached after
tail vein injection and in the liver and spleen. More importantly,
when cells were labeled with Indium-111 and scanned 3 days later
or when Alk phos-labeled cells were imaged by fluorescence 8 days
after transplantation, relatively few BMSCs were found in the
brain, suggesting that the vast majority of cells either did not
successfully cross the infarct-damaged blood-brain-barrier [31] or
perished soon after their arrival there. Similarly, in a recent study
tracking radiolabeled cells after intra-arterial infusion into the
external carotid artery, the majority of cells that made it to the
brain disappeared within 24 hours [24]. Although the brain is
thought to be immune-privileged, it is likely that BMSCs were
eliminated via immune rejection mechanisms [32]. Interestingly,
recent studies using GFP-labeled BMSCs injected directly into
brain parenchyma contrastingly found labeled cells in the brain
many weeks after transplantation [33,34], suggesting that the
absence of BMSCs in the brain in our study may be initiated by
rejection-related mechanisms in the periphery.
Thus, in this regard, it was particularly interesting to find that
the IV injection of BMSCs into the circulation resulted in a rapid
(within 6 hours of treatment) alteration in the composition of
blood. In particular, we noted a significant increase in host
neutrophils, the white blood cells which are the usual first
responders to inflammation [35]. This correlates well with changes
in blood cytokines (ie. VEGF, MIP, MMP2) noted previously after
BMSC treatment by us and others [16,35–37]. Although we did
not look for the enhanced presence of neutrophils in the brain, the
fact that these cells readily migrate across blood vessels suggests
that the increase in circulating neutrophils observed after systemic
BMSCs could readily result in greater numbers of neutrophils or
their products in the brain [31,35]. Also, in regions where there
has been a significant breakdown in the BBB integrity due to the
infarct, white blood cells could gain easy access to the brain,
causing cytokines and chemokines to be released into the
parenchyma [31,32].
Figure 5. Analysis of blood composition before and after
MCAO and rat BMSC treatment. Blood was collected from the tail
vein before and 24 hr after MCAO and 6 and 24 hours after IV injection
of BMSCs and quantitatively analyzed for counts of white blood cells
(WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils
and large unstained cells (LUC) by Bioreliance (Rockville, MD). (N = 3)
*p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0060049.g005
Figure 6. Immunocytochemical analysis of reactive glia and activated microglia in the region of the infarct 4 weeks after BMSC
treatment in MCAO rats. Panel A. Representative section through the brain of MCAO rat (center) showing area of infarction (red). Area in rectangle
on ipsilateral (left) or contralateral (right) sides of MCAO shown enlarged after staining with GFAP (reactive astrocytes) and CD11 (activated microglia)
or merged images in side panels. Panel B. Area labeled ‘‘B’’ in rectangle of Panel A is shown at higher power after staining for GFAP or CD11; Insets:
magnified small rectangles of B. Bars in A and B=100 mm. (N= 4).
doi:10.1371/journal.pone.0060049.g006
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How these stem cell-induced changes modify the well-
documented inflammatory response which occurs in the host
brain after experimental stroke [18,35,38,39] is only now being
explored. We found that BMSC treatment in MCAO rats indeed
results in a marked up-regulation in the number and in the
activation state of local CD11+ microglia and GFAP+ astrocytes,
particularly in the penumbra surrounding the infarct. These
changes persist even at one month after MCAO, that is, several
weeks after the MCAO-induced glial response has returned to
normal [16,40] and the infarcted region has been walled off by
astrocytes in the ischemic brain [16]. Thus, BMSC-induced
cellular alterations in the host glia, combined with the reported
increase in vasculogenesis [41–44], suggests that stem cells and/or
their products play a pivotal role in partitioning off damage, safe-
guarding tissue integrity and/or possibly promoting regeneration
in the brain after experimental stroke.
Of significance, these BMSC-induced cellular changes in brain
were associated with a substantial improvement in all behavioral
indices examined, including those that had partially recovered
spontaneously after MCAO. Thus, at 4 weeks post-MCAO,
performance on the mNSS, climbing and corner turning tests were
significantly improved in the BMSC treatment group compared to
PBS controls. Since 4 weeks was the latest time point examined, in
the future, it will be important to extend the time course of these
studies to determine whether even greater recovery of function is
possible at later time points or after multiple treatments with
BMSCs. A similar lag in functional recovery in electrophysiology,
FMRI and behavioral parameters has indeed been reported
previously [45]. Whether these delayed changes in brain structure
and function owe to direct effects from the increase in blood
neutrophils or from the few BMSCs found in the brain or instead
from secondary processes initiated by their cell products
(cytokines/chemokines/growth factors) remains to be elucidated.
Supporting Information
Figure S1 Immunocytochemical analysis of reactive GFAP+ glia
and activated CD11+ microglia in the striatum on the side of the
infarct at 1 (A, B) and 4 (C,D) weeks after MCAO in PBS-infused
rats. Note that in control (IV infusion of PBS) rats, there is
considerable microglial activation and some astroglial reactivity in
the areas adjacent to the infarct as a result of MCAO. However,
by 4 weeks, much of this activation/reactivity due to MCAO had
receded. Bar = 100 mm. (N = 4).
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